Development of Hypocalcemia Due to Targeted Therapies

Creative Commons License

GÖKÇAY CANPOLAT A., Canlar S., Aydogan B. I., GÜLLÜ S., ERDOĞAN M. F.

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.24, no.1, pp.105-108, 2020 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.25179/tjem.2019-70737
  • Journal Name: TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.105-108
  • Keywords: Erlotinib, vandetanib, hypocalcemia, hypoparathyroidism, PARATHYROID HYPERPLASIA, TGF-ALPHA, EGFR, CANCER
  • Ankara University Affiliated: Yes

Abstract

Novel biological agents are available for the treatment of malignancies, and apart from their utility, they may also have several side effects. The effects on the endocrine system are frequently observed, among which thyroid dysfunctions are common and well-characterized, whereas parathyroid dysfunctions are rare and not well characterized. Herein, we describe two of our patients that displayed hypoparathyroidism and were treated with epidermal growth factor receptor (EGFR) inhibitor erlotinib, vascular endothelial growth factor receptor, and EGFR inhibitor vandetanib.